Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 97 (11), 1589-1600

The PNPLA3 I148M Variant Promotes Lipid-Induced Hepatocyte Secretion of CXC Chemokines Establishing a Tumorigenic Milieu

Affiliations

The PNPLA3 I148M Variant Promotes Lipid-Induced Hepatocyte Secretion of CXC Chemokines Establishing a Tumorigenic Milieu

Hans Dieter Nischalke et al. J Mol Med (Berl).

Abstract

The I148M variant of the Patatin-like phospholipase domain-containing 3 (PNPLA3) protein is associated with an increased risk for liver inflammation and hepatocellular carcinoma (HCC), but the underlying mechanism is unknown. We hypothesized that enhanced CXC chemokine secretion mediates hepatic inflammation that accelerates development of HCC. Expandable primary human (upcyte®) hepatocytes and human PLC/PRF/5 hepatoma cells were lentivirally transduced with both PNPLA3 I148M variants and stimulated with lipids. Cytokine levels in culture supernatant and patient sera (n = 80) were analyzed by ELISA. Supernatants were assessed in transmigration experiments, tube formation, and proliferation assays. In vitro, lipid stimulation of transduced hepatocytes dose-dependently induced the production of interleukin-8 and CXCL1 in hepatocytes carrying the PNPLA3 148M variant. In line, sera from PNPLA3 148M-positive patients with alcoholic liver cirrhosis contained higher levels of interleukin-8 and CXCL1 than patients with wild-type PNPLA3. Supernatants from lipid-stimulated hepatocytes with the PNPLA3 148M variant induced enhanced migration of white blood cells, angiogenesis, and cell proliferation in comparison with supernatants from wild-type hepatocytes via CXC receptors 1 and 2. Increased production of interleukin-8 and CXCL1 by hepatocytes carrying the PNPLA3 148M variant contributes to a pro-inflammatory and tumorigenic milieu in patients with alcoholic liver disease. KEY MESSAGES: The PNPLA3 148M variant is associated with cirrhosis and hepatocellular carcinoma. Lipid stimulation of hepatocytes with this variant induces IL-8 and CXCL1. Supernatants from hepatocytes with this variant promote migration and angiogenesis. Sera from patients with this variant contained enhanced levels of IL-8 and CXCL1. The PNPLA3 148M variant contributes to a tumorigenic milieu via IL-8 and CXCL1.

Keywords: CXCL1; HCC; IL-8; PNPLA3 148M; alcoholic liver disease; cirrhosis; rs738409.

Similar articles

See all similar articles

References

    1. Cancer Cell Int. 2014 Sep 24;14(1):86 - PubMed

References

    1. Am J Gastroenterol. 2014 Mar;109(3):325-34 - PubMed

References

    1. PLoS One. 2011;6(11):e27087 - PubMed

References

    1. Nat Genet. 2010 Jan;42(1):21-3 - PubMed

References

    1. Hepatology. 2017 Jun;65(6):1875-1890 - PubMed

References

    1. Hepatology. 2015 Jan;61(1):108-18 - PubMed

References

    1. PLoS One. 2013 Oct 14;8(10):e75982 - PubMed

References

    1. Br J Cancer. 2015 Sep 1;113(5):756-62 - PubMed

References

    1. Lancet. 2012 Dec 15;380(9859):2095-128 - PubMed

References

    1. J Hepatol. 2014 Jul;61(1):75-81 - PubMed

References

    1. Gastroenterology. 2015 Oct;149(4):1053-67.e14 - PubMed

References

    1. PLoS One. 2013 Nov 18;8(11):e80848 - PubMed

References

    1. J Am Soc Nephrol. 2005 May;16(5):1266-78 - PubMed

References

    1. Mol Metab. 2019 Apr;22:49-61 - PubMed

References

    1. Hepatology. 2017 Oct;66(4):1111-1124 - PubMed

References

    1. Nat Immunol. 2018 Mar;19(3):222-232 - PubMed

References

    1. Gastroenterology. 2014 Sep;147(3):577-594.e1 - PubMed

References

    1. Hepatology. 2014 Jun;59(6):2170-7 - PubMed

References

    1. J Lipid Res. 2009 Oct;50(10):2111-6 - PubMed

References

    1. Am J Gastroenterol. 2015 Jun;110(6):846-56 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2031-41 - PubMed

References

    1. FEBS J. 2018 Feb;285(4):752-762 - PubMed

References

    1. PLoS One. 2011;6(6):e21381 - PubMed

References

    1. Nat Genet. 2015 Dec;47(12):1443-8 - PubMed

References

    1. Mol Carcinog. 2013 Nov;52 Suppl 1:E139-47 - PubMed

References

    1. J Hepatol. 2016 Aug;65(2):399-412 - PubMed

References

    1. Clin Lab. 2013;59(9-10):969-76 - PubMed

References

    1. J Intern Med. 2018 Apr;283(4):356-370 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2019 May 7;116(19):9521-9526 - PubMed

References

    1. Hum Mol Genet. 2014 Aug 1;23(15):4077-85 - PubMed

References

    1. J Hepatol. 2018 Feb;68(2):280-295 - PubMed

References

    1. Mol Biol Cell. 2015 Jun 15;26(12):2190-204 - PubMed

References

    1. Nat Genet. 2008 Dec;40(12):1461-5 - PubMed

References

    1. Hepatology. 2010 Sep;52(3):894-903 - PubMed

References

    1. Int J Oncol. 2015 Dec;47(6):2131-40 - PubMed

References

    1. Liver Int. 2017 Feb;37(2):280-289 - PubMed

References

    1. J Lipid Res. 2011 Feb;52(2):318-29 - PubMed

References

    1. J Gastroenterol Hepatol. 2015 Jan;30(1):139-46 - PubMed

References

    1. Endocrinology. 2012 May;153(5):2164-77 - PubMed

References

    1. Hepatology. 2012 Dec;56(6):2242-54 - PubMed

References

    1. Oncotarget. 2016 Oct 4;7(40):65052-65066 - PubMed

References

    1. Cancer Lett. 2009 Jul 8;279(2):163-70 - PubMed

References

    1. Future Med Chem. 2012 May;4(7):853-67 - PubMed

References

    1. Hepatology. 2007 Sep;46(3):823-30 - PubMed

References

    1. J Clin Invest. 2012 Nov;122(11):4130-44 - PubMed

References

    1. Am J Gastroenterol. 2018 Oct;113(10):1475-1483 - PubMed

References

    1. Hepatology. 2010 Sep;52(3):904-12 - PubMed

References

    1. Nat Protoc. 2009;4(4):495-505 - PubMed

References

    1. J Biol Chem. 2011 Oct 28;286(43):37085-93 - PubMed

LinkOut - more resources

Feedback